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Importance of the TIMI frame count: implications for future trials
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Abstract
Although the TIMI (Thrombolysis In Myocardial Infarction) flow grade classification scheme is
widely used to assess angiographic outcomes, it is limited by poor reproducibility and its
categoric nature. The corrected TIMI frame count (CTFC) is a simple, more objective
continuous variable index of coronary blood flow that can be broadly and inexpensively
applied. This measure of the time for dye to traverse a coronary artery is both accurate
(highly correlated with Doppler velocity measurements) and precise (reproducible). The
method has been prospectively validated as providing independent risk stratification above
and beyond the conventional TIMI flow grades. It has been shown to be a predictor of
restenosis, and has been of value in elucidating the underlying pathophysiology of acute
myocardial infarction. In view of the above and its ease of use, we anticipate that CTFC will
become a widely used method to evaluate coronary blood flow.
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Introduction
The TIMI (Thrombolysis in Myocardial Infarction) flow
grade is a widely used method for the assessment of coro-
nary artery flow in acute coronary syndromes. Flow in
coronary arteries is classified as grade 0 (no flow),
grade 1 (penetration without perfusion), grade 2 (partial
perfusion) or grade 3 (complete perfusion). TIMI grade 3
flow requires that antegrade flow distally be as rapid as
antegrade flow proximally. The PAMI (Primary Angioplasty
in Myocardial Infarction) investigators have redefined TIMI
grade 3 flow as opacification of the vessel within three
cardiac cycles (ie ‘PAMI’ grade 3 flow) [1]. This new defin-
ition increases the number of arteries that are considered
to have normal flow by about 10% over the original defini-
tion of TIMI grade 3 flow, requiring adjustment of analyses
comparing original and redefined TIMI grade 3 flows [2].
Limitations of the TIMI flow method
The TIMI flow method for defining coronary artery flow has
proven useful in assessing reperfusion strategies over the
past 15 years. However, a number of limitations have
become apparent. TIMI flow grade assessment is limited
by interobserver variability (core laboratories agree 71% of
the time) [3] and by the need for a more objective quantifi-
cation of the different degrees of complete perfusion in a
coronary artery. In order to overcome these problems, the
TIMI frame count was developed as a more quantitative
index of coronary artery flow [4].Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Appleby et al
Corrected TIMI frame count
Technique
In the CTFC method, the number of frames required for dye
to reach a standardized distal landmark is counted. A correc-
tion factor is required to compensate for the longer length of
the left anterior descending artery (LAD) compared with the
circumflex and right coronary arteries (the number of frames
required for dye to traverse the LAD is divided by 1.7). The
frame count number after adjustment for vessel length is
given the term ‘corrected TIMI frame count’ [4].
The first frame taken for measurements is the frame in which
dye touches both borders of the coronary artery and moves
forward with at least 70% opacification of the vessel lumen.
The standardized distal landmarks are taken as the first
branch of the posterolateral artery for the right coronary
artery, most distal branch of the obtuse marginal branch for
the circumflex, and the distal bifurcation for the LAD (also
known as the ‘whale’s tail’ branch of the LAD). The number
of frames from the first frame to the last frame when dye
enters the standardized distal landmark is counted. Centers
that use image acquisition at speeds other than the most
widely used frame rate in the US of 30 frames/s need to
adjust CTFC assessments accordingly. For example, in the
use of images acquired at 15 frames/s, frame counts are
multiplied by a factor of 2 to derive the CTFC.
Highly reproducible results are obtained with very low
interobserver and intraobserver variability [4]. Differences
between observers are less than 0.75 frames [5] and the
correlation between observers is 0.97–0.99 [6]. Varying
the force of dye injection may change the frame count by
up to 2 frames, which is a relatively small and insignificant
difference from a clinical trial perspective [7]. Alterations
in catheter size do not affect CTFC measurements [8].
Administration of nitrates, which cause enlargement of the
artery and the volume to be filled with dye significantly,
increases the CTFC by approximately 6 frames [8]. It is
therefore important to standardize use of nitrates in
studies that involve CTFC measurement, or to at least
confirm that nitrate use is well balanced across arms of
the trial. Injections during diastole reduce the CTFC by 6
frames [8]. Pacing at a faster heart rate (20 beats/min)
reduced the CTFC by 5 frames [8].
Applications
The CTFC technique is a simple and inexpensive tech-
nique for calculation of coronary flow reserve, and is highly
correlated (r=0.88,  P=0.0001) with coronary flow
reserve measurements obtained using the Doppler
guidewire [9]. It is also correlated with volumetric flow and
resting distal average peak velocity [6]. Distance along
coronary arteries measured using angioplasty guidewires
may be combined with TIMI frame count measurements to
give absolute velocity and flow assessments that are sen-
sitive to small changes in perfusion [10]. Indeed, although
patients often have TIMI grade 3 flow both before and
after the intervention, the velocity may in fact double in
these patients [10]. Flow in coronary arteries after myocar-
dial infarction or percutaneous coronary intervention is uni-
modally distributed across a broad range. By using the
continuous variable of CTFC, it is apparent that not all
TIMI grade 3 flows are created equally, and TIMI grade 3
flow can be subdivided into a wide range of velocities,
providing greater risk stratification within TIMI grade 3 flow
[11].
Use of the more precise CTFC has resulted in a number of
interesting observations. A normal frame count is 21±3
[4]. TIMI grade 3 flow in coronary arteries after thromboly-
sis is actually slower than normal (35.6±20.8). Further-
more, previous thrombolysis studies using TIMI flow
assessments have assumed basal flow in the nonculprit
artery to be normal. However, assessment of CTFC has
demonstrated a 45% higher frame count (21 versus 31
frames) for basal flow in the uninvolved artery [12]. This
global impairment of flow in all three arteries is related to a
higher risk of mortality [12]. As flow improves in the culprit
artery in the setting of an acute myocardial infarction, flow
also increases in the nonculprit artery. Variables other than
lumen geometry slow flow in acute myocardial infarction;
longer lengths of artery distal to the stenosis (more
myocardium jeopardized), delayed achievement of
patency, LAD location, and the presence of thrombus are
all related to slower culprit artery flow [13].
By comparing the CTFC associated with different throm-
bolytic regimens, pharmacologic efficacy can be deter-
mined with greater statistical sensitivity compared with the
previously used TIMI flow grades [14]. It is entirely possi-
ble that two drugs might have the same rate of TIMI
grade 3 flow, but the velocity of TIMI grade 3 flow may be
faster for one drug compared with another. As pharmaco-
logic efficacy improves, the need to be able to discern
subtle differences in flow also increases. Indeed, the
CTFC was a sensitive measure of efficacy in the TIMI-14
trial of combination therapy [15].
CTFC measurements are very useful in predicting clinical
outcomes. Low CTFCs after reperfusion in myocardial
infarction are associated with low mortality rates. Indeed,
we have again shown that not all TIMI grade 3 flows are
created equally, and that even faster TIMI grade 3 flow is
associated with even better outcomes. For example, those
patients with a CTFC of less than 14 after thrombolysis
sustained 0.0% mortality in acute myocardial infarction
[16]. This hyperemic flow is what we have now come to
term ‘TIMI grade 4 flow’. The CTFC 90 min after myocar-
dial infarction has been shown to predict left ventricular
function at 48 h after myocardial infarction [17]. The CTFC
measured 90 min after thrombolysis has also been related
to improved in-hospital and 1-month clinical outcomesc
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[16]. Furthermore, CTFC at 1 month after myocardial
infarction is highly correlated with infarct-related flow at 1
year [5]. Finally, repeat angiography after myocardial
infarction or unstable angina demonstrates continued
impairment in coronary artery flow 10 weeks after presen-
tation [18], and CTFC measurements are also a predictor
of reocclusion in patent infarct-related arteries [19].
The CTFC has been shown to be of value in the evaluation
of percutaneous interventions. The CTFC divided by the
minimum lumen diameter at the end of the intervention
was the most powerful predictor of restenosis in a recent
report [6]. Thus, both ‘bigger and faster’ is better [6].
Indeed, we have shown that the CTFC is of independent
predictive value with respect to restenosis above and
beyond the minimum lumen diameter and the reference
diameter. We have also shown that it is related to mortality
after coronary intervention in the setting of unstable angina
and non-Q-wave myocardial infarction [20]. Stenting in
acute myocardial infarction has been associated with a
greater improvement in coronary artery flow as measured
using the CTFC method [21].
Although establishing flow in acute myocardial infarction is
important, this does not necessarily result in microvascular
perfusion at the tissue level [22]. We have recently demon-
strated [22] that inadequate perfusion of the myocardium
using the TIMI myocardial perfusion grade is related to
higher mortality. Despite achieving normal epicardial TIMI
grade 3 flow or a CTFC of below 40, those patients with a
closed microvasculature (TIMI myocardial perfusion
grade 0, a pale myocardium) had a mortality of over 5%,
whereas those patients with normal perfusion at the level of
the myocardium (TIMI myocardial perfusion grade 3 flow)
had a mortality of under 1%. Thus, restoration of epicardial
blood flow is adequate, but not sufficient to ensure an
optimal outcome. It is the restoration of flow at both the
epicardial and tissue level that yields the best clinical out-
comes. We have shown that those patients with a residual
impairment of flow (a CTFC >28) despite a minimal 16%
residual stenosis have a mortality rate 12 times higher than
that in patients with normal flow. This again points to the
critical nature of the microvasculature in determining out-
comes, despite the relief of the stenosis [13].
Conclusion
The TIMI Frame Count is accurate and precise. Its simplic-
ity and ease of use should allow it to be broadly applied to
provide further insight into pathophysiology and the effi-
cacy of reperfusion strategies
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